Skip to main content
. 2022 Mar 17;64:151–158. doi: 10.1016/j.breast.2022.03.001

Fig. 2.

Fig. 2

Final analysis of DFS of SafeHER for the (A) entire ITT population, (B) no chemotherapy subgroup, (C) concurrent chemotherapy subgroup, and (D) sequential chemotherapy subgroup. DFS, disease-free survival; ITT, intent-to-treat.